20 May, 2023 New Results from APOLLO-B Phase 3 Study of Patisiran Presented during Heart Failure 2023
Eighteen month results from the APOLLO-B Phase 3 study of patisiran in patients with ATTR amyloidosis with cardiomyopathy were presented at the Annual Congress of the Heart Failure Association of the European Society of Cardiology (Heart Failure 2023). A post-hoc analysis of the APOLLO-B study assessing the efficacy of patisiran in patients with hATTR amyloidosis with cardiomyopathy and polyneuropathy (mixed phenotype) was also presented.
Fontana, et al. “Patisiran Treatment for ATTR Cardiac Amyloidosis: 18-Month Results of the Phase 3 APOLLO-B Study”
Gustafsson, et al. “Effect of Patisiran Treatment in Patients with hATTR Amyloidosis with Cardiomyopathy and Polyneuropathy: Post-hoc Analysis of the APOLLO-B Study”